Related Experiment Video
Updated: Aug 18, 2026
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Carcinogenicity of chrysazin in large intestine and liver of mice
Abstract:
The carcinogenicity of chrysazin (1,8-dihydroxy-9,10-anthracenedione) was examined by dietary administration to C3H/HeN mice. All of the effective mice (17) which were given 0.2% chrysazin diet and which survived more than 500 days developed adenomatous hyperplasia with cystic glands of the cecum. Similar lesions were also seen in the colon of mice in this group. These intestinal lesions were not obtained in any effective mouse (19) of the control group. The incidence of hepatocellular carcinoma of mice given chrysazin (4/17) was significantly higher than that of the controls (0/19). These results indicate that chrysazin is carcinogenic in mice as well as in rats. Some mechanistic aspects of the causation of these intestinal lesions and liver neoplasms are also discussed.
Insights
Chrysazin (1,8-dihydroxy-9,10-anthracenedione) is carcinogenic in mice, causing intestinal lesions and increasing liver cancer risk. This study confirms chrysazin
Area of Science:
- Toxicology
- Carcinogenesis
- Animal Studies
Background:
- Chrysazin (1,8-dihydroxy-9,10-anthracenedione) is a compound with potential health implications.
- Previous studies have suggested carcinogenicity in rats, warranting further investigation.
Purpose of the Study:
- To evaluate the carcinogenicity of chrysazin in a mouse model.
- To identify specific target organs and lesion types induced by chrysazin exposure.
Main Methods:
- Dietary administration of chrysazin (0.2% concentration) to C3H/HeN mice.
- Long-term survival study (over 500 days) with control groups for comparison.
- Histopathological examination of intestinal and liver tissues.
Main Results:
- Significant development of adenomatous hyperplasia with cystic glands in the cecum and colon of mice fed chrysazin.
- Absence of similar intestinal lesions in the control group.
- A statistically significant increase in hepatocellular carcinoma incidence (4/17) in the chrysazin-treated group compared to controls (0/19).
Conclusions:
- Chrysazin demonstrates carcinogenicity in mice, inducing both intestinal lesions and liver neoplasms.
- The findings support and extend previous evidence of chrysazin's carcinogenic potential.
- Further research into the mechanisms underlying chrysazin-induced carcinogenesis is warranted.
More Related Videos
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
06:24Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
Published on: October 13, 2023
